Study of HS-10566 for high-risk bladder cancer that hasn't spread into muscle
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new treatment called HS-10566 for people with a type of bladder cancer that has not reached the muscle layer and is considered high-risk, where the usual treatments have not worked or were not an option. It aims to control the cancer and avoid the need for removing the bladder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with non-muscle-invasive bladder cancer (a type of bladder cancer that hasn't spread into the muscle layer of the bladder).
- You must have had surgery to remove the tumor (TURBT) within the past 12 weeks.
- You must either have had bladder cancer that didn't respond well to BCG therapy, or you have never had BCG treatment (or stopped it more than 3 years ago).
- You must be ineligible for or choose not to have your bladder removed (radical cystectomy).
- You must have adequate bone marrow, liver, and kidney function, and be fairly active (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
This trial tests whether a new bladder cancer drug (SHR-1501) works alone or combined with BCG, and compares options with another drug (SHR-1316), in people with high-risk non–muscle-invasive bladder cancer. It may help reduce cancer coming back and improve control of the disease.
This study tests a new immunotherapy drug (SHR-1501) combined with standard BCG therapy for people with a specific type of early bladder cancer (papillary-only, high-risk). The goal is to see if the combination helps prevent cancer from returning better than BCG alone.
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
Hear when a new High Risk Non-muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.